Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 3/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22827545 | 0.84 | PDCD1 (0.47) | ACVR2ATGFBR2NLRP3IDO1DYRK1A | |
| SCHEMBL24478079 | 0.84 | ACVR2A (0.44) | ACVR2ATGFBR2NLRP3IDO1DYRK1A | |
| SCHEMBL22827688 | 0.83 | ACVR2A (0.43) | ACVR2ATGFBR2NLRP3IDO1DYRK1A | |
| SCHEMBL23063148 | 0.83 | NLRP3 (0.45) | ACVR2ATGFBR2NLRP3IDO1DYRK1A | |
| SCHEMBL25203368 | 0.81 | PDCD1 (0.43) | ACVR2ATGFBR2IDO1DYRK1APDCD1 | |
| SCHEMBL20609796 | 0.81 | NLRP3 (0.48) | ACVR2ATGFBR2NLRP3IDO1DYRK1A | |
| SCHEMBL29927552 | 0.81 | NLRP3 (0.48) | ACVR2ATGFBR2NLRP3IDO1DYRK1A | |
| SCHEMBL22014327 | 0.81 | NLRP3 (0.42) | ACVR2ATGFBR2NLRP3IDO1DYRK1A | |
| SCHEMBL20876023 | 0.80 | NLRP3 (0.49) | ACVR2ATGFBR2NLRP3IDO1DYRK1A | |
| SCHEMBL25793853 | 0.78 | AAK1 (0.40) | ACVR2ATGFBR2NLRP3IDO1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219920-A1 | DIMETHYLSULFOXIMINE DERIVATIVE | CISEN PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219920-A1 | DIMETHYLSULFOXIMINE DERIVATIVE | CISEN PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4166541-A1 | DIMETHYLSULFOXIMINE DERIVATIVE | Medshine Discovery Inc. (CN) | 2023-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219920-A1 | DIMETHYLSULFOXIMINE DERIVATIVE | SRM, STS, SMS | ACVR2A 4455/4885TGFBR2 2838/4885NLRP3 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.